These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10339976)

  • 1. [Long-term outcome of topical cyclosporine treatment following penetrating keratoplasty].
    Inoue K; Amano S; Kimura C; Sato T; Fujita N; Kagaya F; Kaji Y; Oshika T; Tsuru T; Araie M
    Nippon Ganka Gakkai Zasshi; 1999 Apr; 103(4):306-10. PubMed ID: 10339976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical cyclosporine in pediatric keratoplasty.
    Cosar CB; Laibson PR; Cohen EJ; Rapuano CJ
    Eye Contact Lens; 2003 Apr; 29(2):103-7. PubMed ID: 12695714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty.
    Inoue K; Amano S; Kimura C; Sato T; Fujita N; Kagaya F; Kaji Y; Oshika T; Tsuru T; Araie M
    Jpn J Ophthalmol; 2000; 44(3):302-5. PubMed ID: 10913651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of topical cyclosporine A on keratoplasty rejection in rats].
    Zhang W; Pan Z; Zhai C
    Zhonghua Yan Ke Za Zhi; 2001 Mar; 37(2):140-3. PubMed ID: 11864411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel cyclosporine a drug-delivery system for prevention of human corneal rejection after high-risk keratoplasty: a clinical study.
    Shi W; Chen M; Xie L; Liu M; Gao H; Wang T; Wu X; Zhao J
    Ophthalmology; 2013 Apr; 120(4):695-702. PubMed ID: 23246118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term comparison of full-bed deep lamellar keratoplasty with penetrating keratoplasty in treating corneal leucoma caused by herpes simplex keratitis.
    Wu SQ; Zhou P; Zhang B; Qiu WY; Yao YF
    Am J Ophthalmol; 2012 Feb; 153(2):291-299.e2. PubMed ID: 21996306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of topical ciclosporin 0.05% for prevention of rejection in high-risk corneal grafts.
    Unal M; Yücel I
    Br J Ophthalmol; 2008 Oct; 92(10):1411-4. PubMed ID: 18662913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial.
    Sinha R; Jhanji V; Verma K; Sharma N; Biswas NR; Vajpayee RB
    Graefes Arch Clin Exp Ophthalmol; 2010 Aug; 248(8):1167-72. PubMed ID: 20414783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats.
    Bourges JL; Lallemand F; Agla E; Besseghir K; Dumont JM; BenEzra D; Gurny R; Behar-Cohen F
    Mol Vis; 2006 Dec; 12():1461-6. PubMed ID: 17167400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of topical ciclosporin A for treatment and prevention of graft rejection in corneal grafts with previous rejection episodes.
    Javadi MA; Feizi S; Karbasian A; Rastegarpour A
    Br J Ophthalmol; 2010 Nov; 94(11):1464-7. PubMed ID: 20576763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.
    Di Tommaso C; Bourges JL; Valamanesh F; Trubitsyn G; Torriglia A; Jeanny JC; Behar-Cohen F; Gurny R; Möller M
    Eur J Pharm Biopharm; 2012 Jun; 81(2):257-64. PubMed ID: 22445900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat.
    Juberías JR; Calonge M; Gómez S; López MI; Calvo P; Herreras JM; Alonso MJ
    Curr Eye Res; 1998 Jan; 17(1):39-46. PubMed ID: 9472469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes.
    Price MO; Price FW
    Ophthalmology; 2006 Oct; 113(10):1785-90. PubMed ID: 16884779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cyclosporin A combined with dexamethasone in preventing and treating immune rejection after penetrating keratoplasty].
    Xi XH; Qin B; Jiang DY
    Hunan Yi Ke Da Xue Xue Bao; 2003 Dec; 28(6):627-30. PubMed ID: 15804077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Penetrating keratoplasty in high-risk children: prevention of graft rejection].
    Pleskova AV; Khvatova AV
    Vestn Oftalmol; 2014; 130(3):17-20. PubMed ID: 25098116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Keratoplasty postoperative treatment update.
    Shimmura-Tomita M; Shimmura S; Satake Y; Shimazaki-Den S; Omoto M; Tsubota K; Shimazaki J
    Cornea; 2013 Nov; 32 Suppl 1():S60-4. PubMed ID: 24104936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of treatment of mooren ulcer with topical cyclosporine a 2%.
    Tandon R; Chawla B; Verma K; Sharma N; Titiyal JS
    Cornea; 2008 Sep; 27(8):859-61. PubMed ID: 18724142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of systemic tacrolimus in high-risk penetrating keratoplasty after graft failure with systemic cyclosporine.
    Yamazoe K; Yamazoe K; Yamaguchi T; Omoto M; Shimazaki J
    Cornea; 2014 Nov; 33(11):1157-63. PubMed ID: 25255133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose subconjunctival cyclosporine a implants do not affect corneal neovascularization after high-risk keratoplasty.
    Bock F; Matthaei M; Reinhard T; Böhringer D; Christoph J; Ganslandt T; Cursiefen C
    Ophthalmology; 2014 Sep; 121(9):1677-82. PubMed ID: 24780407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse effects of low-dose systemic cyclosporine therapy in high-risk penetrating keratoplasty.
    Lee JJ; Kim MK; Wee WR
    Graefes Arch Clin Exp Ophthalmol; 2015 Jul; 253(7):1111-9. PubMed ID: 25896110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.